ID
40934
Description
Open-label, Phase II, Study of Everolimus Plus Letrozole in Postmenopausal Women With ER+, HER2- Metastatic or Locally Advanced Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01698918
Lien
https://clinicaltrials.gov/show/NCT01698918
Mots-clés
Versions (1)
- 07/06/2020 07/06/2020 -
Détendeur de droits
See clinicaltrials.gov
Téléchargé le
7 juin 2020
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Hormone Receptor Positive Breast Cancer NCT01698918
Eligibility Hormone Receptor Positive Breast Cancer NCT01698918
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Non-Measurable Lesion | Exception Secondary malignant neoplasm of bone | Pleural effusion | Ascites
Type de données
boolean
Alias
- UMLS CUI [1]
- C1334988
- UMLS CUI [2,1]
- C1705847
- UMLS CUI [2,2]
- C0153690
- UMLS CUI [3]
- C0032227
- UMLS CUI [4]
- C0003962
Description
Prior Hormone Therapy Secondary malignant neoplasm of female breast | Systemic therapy Secondary malignant neoplasm of female breast
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C1514460
- UMLS CUI [1,2]
- C0346993
- UMLS CUI [2,1]
- C1515119
- UMLS CUI [2,2]
- C0346993
Description
Hormone Therapy Neoadjuvant allowed | Prior adjuvant endocrine therapy allowed | NSAID Neoadjuvant Treatment completed | NSAID Adjuvant Treatment completed | Letrozole Treatment completed | Anastrozole Treatment completed
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0279025
- UMLS CUI [1,2]
- C0600558
- UMLS CUI [1,3]
- C0683607
- UMLS CUI [2,1]
- C0281266
- UMLS CUI [2,2]
- C0683607
- UMLS CUI [3,1]
- C0003211
- UMLS CUI [3,2]
- C0600558
- UMLS CUI [3,3]
- C0580352
- UMLS CUI [4,1]
- C0003211
- UMLS CUI [4,2]
- C1522673
- UMLS CUI [4,3]
- C0580352
- UMLS CUI [5,1]
- C0246421
- UMLS CUI [5,2]
- C0580352
- UMLS CUI [6,1]
- C0290883
- UMLS CUI [6,2]
- C0580352
Description
mTOR Inhibitors
Type de données
boolean
Alias
- UMLS CUI [1]
- C1515672
Description
Hypersensitivity mTOR Inhibitors | Hypersensitivity Sirolimus
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0020517
- UMLS CUI [1,2]
- C1515672
- UMLS CUI [2,1]
- C0020517
- UMLS CUI [2,2]
- C0072980
Description
Eligibility Criteria Study Protocol
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C2348563
Similar models
Eligibility Hormone Receptor Positive Breast Cancer NCT01698918
- StudyEvent: Eligibility
C1519810 (UMLS CUI [1,2])
C3495949 (UMLS CUI [2,1])
C1519810 (UMLS CUI [2,2])
C0346993 (UMLS CUI [3,1])
C1548788 (UMLS CUI [3,2])
C1511562 (UMLS CUI [3,3])
C3495949 (UMLS CUI [4,1])
C1548788 (UMLS CUI [4,2])
C1511562 (UMLS CUI [4,3])
C0346993 (UMLS CUI [5,1])
C1548788 (UMLS CUI [5,2])
C1522449 (UMLS CUI [5,3])
C1276305 (UMLS CUI [5,4])
C3495949 (UMLS CUI [6,1])
C1548788 (UMLS CUI [6,2])
C1522449 (UMLS CUI [6,3])
C1276305 (UMLS CUI [6,4])
C0279754 (UMLS CUI [1,2])
C2348908 (UMLS CUI [1,3])
C0332197 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0153690 (UMLS CUI [2,2])
C0032227 (UMLS CUI [3])
C0003962 (UMLS CUI [4])
C0346993 (UMLS CUI [1,2])
C1515119 (UMLS CUI [2,1])
C0346993 (UMLS CUI [2,2])
C0600558 (UMLS CUI [1,2])
C0683607 (UMLS CUI [1,3])
C0281266 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
C0003211 (UMLS CUI [3,1])
C0600558 (UMLS CUI [3,2])
C0580352 (UMLS CUI [3,3])
C0003211 (UMLS CUI [4,1])
C1522673 (UMLS CUI [4,2])
C0580352 (UMLS CUI [4,3])
C0246421 (UMLS CUI [5,1])
C0580352 (UMLS CUI [5,2])
C0290883 (UMLS CUI [6,1])
C0580352 (UMLS CUI [6,2])
C1515672 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0072980 (UMLS CUI [2,2])
C2348563 (UMLS CUI [1,2])